CN109422786A - Benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes - Google Patents
Benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes Download PDFInfo
- Publication number
- CN109422786A CN109422786A CN201710724964.4A CN201710724964A CN109422786A CN 109422786 A CN109422786 A CN 109422786A CN 201710724964 A CN201710724964 A CN 201710724964A CN 109422786 A CN109422786 A CN 109422786A
- Authority
- CN
- China
- Prior art keywords
- theaflavin
- compound
- preparation
- formula
- gallate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- -1 phenol ketone Chemical class 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 7
- 102000030523 Catechol oxidase Human genes 0.000 claims description 18
- 108010031396 Catechol oxidase Proteins 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 4
- 125000003147 glycosyl group Chemical group 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000006911 enzymatic reaction Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 abstract description 46
- 235000014620 theaflavin Nutrition 0.000 abstract description 42
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 abstract description 41
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 abstract description 41
- 229940026509 theaflavin Drugs 0.000 abstract description 41
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 abstract description 27
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 abstract description 27
- AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 abstract description 17
- 229920002707 Digallic acid Polymers 0.000 abstract description 16
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 abstract description 15
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 abstract description 15
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 abstract description 15
- AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 abstract description 12
- 235000007900 theaflavin-3-gallate Nutrition 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 11
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 125000005605 benzo group Chemical group 0.000 abstract description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 28
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 13
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003925 fat Substances 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 235000011430 Malus pumila Nutrition 0.000 description 6
- 235000015103 Malus silvestris Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 4
- 241000220324 Pyrus Species 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 4
- 235000007743 myricetin Nutrition 0.000 description 4
- 229940116852 myricetin Drugs 0.000 description 4
- 229920006122 polyamide resin Polymers 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000003519 ventilatory effect Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 241001593750 Turcica Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 235000021017 pears Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241001290175 Coriolopsis trogii Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 229960005060 lorcaserin Drugs 0.000 description 2
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005360 mashing Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940103440 qsymia Drugs 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002485 serotonin 2C agonist Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to drug or field of health care products, and in particular to benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes.The benzo Zhuo phenol ketone derivatives have the following structure:
Description
Technical field
The invention belongs to drug or field of health care products, and in particular to benzo Zhuo phenol ketone derivatives and preparation method thereof with
On the way.
Background technique
Obesity is a kind of chronic metabolic disease as caused by many factors, with the volume and cell of body fat cell
Number, which increases, causes the percentage of body fat percentage of liveweight to increase extremely and with the characteristics of certain parts excessively deposit fat.Numerous studies table
Bright, obesity can cause a variety of chronic diseases such as hypertension, diabetes, coronary heart disease, it has also become global serious public to defend
Raw problem.According to statistics, 2015, population of being obese quantity was respectively 1.077 hundred million and 6.037 hundred million in global children and in adult,
The same year whole world about cause of the death of 4,000,000 people is directly related with high BMI, accounts for the 7.1% of whole death tolls.
Current slimming drugs mainly include following two major classes: pancreatic lipase inhibitor and appetite inhibitor；Pancreatic lipase suppression
Preparation is by inhibiting pancreatic lipase activity, inhibiting fatty decomposition absorption in food and lose weight, and appetite inhibitor is due to can
Cause nervous system adverse reaction and is used by limitation.So far, the slimming drugs that can be used for a long time through FDA approval only have fat
Enzyme inhibitor orlistat (orlistat), serotonin 2C receptor stimulating agent lorcaserin (lorcaserin) and compound slimming
Medicine Qsymia (sustained release agent containing phentermine and Topiramate).However, above-mentioned slimming drugs can cause steatorrhea, liposoluble vitamin
The adverse reactions such as shortage, and to brain centres and cardiovascular system etc., whether toxic side effect still has very big do not know
Property.
Hyperlipidemia is that fat metabolism or operating exception make one or more lipid levels in blood plasma be higher than the complete of normal value
Body disease is mainly characterized by triacylglycerol in serum (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C)
Level increases, and high-density lipoprotein cholesterol (HDL-C) is horizontal to be reduced.Hyperlipidemia be cause cardiovascular and cerebrovascular disease the reason of it
One.According to statistics, there are about 12,000,000 people to die of cardiovascular and cerebrovascular disease every year in the whole world.Currently, the clinical first-line drug of reducing blood lipid is main
It is curative for effect, rapid-action for statins, but have the shortcomings that easily rebound, high recurrence rate and need Long-term taking medicine.
2001, cerivastatin caused to quit listing because the lethal serious adverse reaction of rhabdomyolysis occurs for pill taker, while also causing
It worry to the safety of other statins and discusses warmly.
Theaflavin (theaflavins, TFs) is found by Roberts E.A.H. in nineteen fifty-seven earliest, is polyphenols
One kind that oxidation is formed has the general name of the compound of benzo Zhuo phenolic ketone structure, passes through C2-C4, C2-C6 key and 2 benzene a pair of horses going side by side dihydros
Pyranoid ring is connected, and singly-bound is rotated freely by steric interference, to form specific space conformation.It has been reported that
Theaflavin can reduce rat body weight and Fat Accumulation, can also improve lipid-metabolism with regulating blood lipoid level.
Therefore, the novel benzo Tropolones compound with fat-reducing and antihyperglycemic is studied to have great importance.
Summary of the invention
For this purpose, the present invention provides a kind of novel benzo Tropolones compound, and then provide preparation method and purposes.
In order to solve the above technical problems, the present invention is achieved through the following technical solutions:
The present invention provides the compound with structure shown in formula (I),
Wherein, R1、R2Be independently from each other H, by In
At least one be formed by glycosyl residue.
Preferably, above compound,
R1Selected from H, byAt least one of be formed by glycosyl residue, R2Choosing
From H.
It is further preferred that above compound,
R1Selected from H,
It is further preferred that above compound, formula (I) compound represented is selected from:
The present invention also provides the pharmaceutically acceptable salt of above compound, ester, prodrug, solvate or its crystal forms.
The present invention also provides a kind of pharmaceutical preparations, with above compound, its pharmaceutically acceptable salt, ester, prodrug, solvent
It closes object or its crystal form is active constituent, according to common process, customary adjuvant is added, clinically acceptable tablet, capsule is made
Agent, powder, mixture, pill, granule, syrup, emplastrum, suppository, aerosol, ointment or injection.
The customary adjuvant are as follows: filler, disintegrating agent, lubricant, suspending agent, adhesive, sweetener, corrigent, anti-corrosion
Agent, matrix etc..Filler includes: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；It collapses
Solving agent includes: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low substitution hydroxyl
Third cellulose, cross-linked carboxymethyl cellulose are received；Lubricant includes: magnesium stearate, lauryl sodium sulfate, talcum powder, dioxy
SiClx etc.；Suspending agent includes: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Bonding
Agent includes starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；Sweetener includes: saccharin sodium, aspartame, sugarcane
Sugar, honey element, enoxolone etc.；Corrigent includes: sweetener and various essence；Preservative include: parabens, benzoic acid,
Sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc.；Matrix include: PEG6000,
PEG4000, insect wax etc..
The present invention also provides a kind of method for preparing above compound, shown in formula (II) compound represented and formula (III)
Compound is under the action of polyphenol oxidase by enzymatic reaction up to formula (I) compound represented；
Preferably, above-mentioned preparation method, formula (II) compound represented and the molar ratio of formula (III) compound represented are
(1:2)~(2:1)；
It is further preferred that the molar ratio of formula (II) compound represented and formula (III) compound represented is 1:1.
Preferably, above-mentioned preparation method is changed shown in formula (II) using citrate-phosphate disodium hydrogen buffer as reaction solution
It closes object and total concentration of formula (III) compound represented in reaction solution is 1~2.7g/100mL.
It is further preferred that above-mentioned preparation method, pH value in reaction is 3.5~4.5, and reaction temperature is 25~35 DEG C, reaction
Time is 0.75~2h, and the additional amount of the polyphenol oxidase is 1.5~2.5g/L, and minute ventilation volume is the reaction liquid
1~2 times of long-pending amount.
It is further preferred that above-mentioned preparation method, the source object of the polyphenol oxidase is selected from: fruit, plant, micro- life
Object.
It is further preferred that above-mentioned preparation method, the source object of the polyphenol oxidase is selected from:
A, fruit: loquat, blue poison, apple, pears, peach, grape, lichee, apricot, pineapple；
B, plant: green tea, oolong tea, potato bud/root, spinach, semen viciae fabae, carrot, tomato；
C, microorganism: tea tree endophyte, Trametes trogii, hard Trametes trogii and Corilus versicolor Quel..
The present invention also provides above compounds or said medicine preparation to have the drug or health care product of antiobesity action in preparation
In application.
The present invention also provides above compounds or said medicine preparation to have drug or the health care of effect for reducing blood fat in preparation
Application in product.
The present invention also provides above compounds or said medicine preparation in preparation prevention or treats drug or the guarantor of fatty liver
Application in strong product.
Technical solution of the present invention has the advantages that
(1) the compounds of this invention inhibits the increased significant effect of mouse weight to be better than theaflavin, theaflavin -3- gallic acid
Ester, theaflavin-3'-gallate and theaflavin -3,3 '-digallic acid ester inhibit the increased effect of mouse weight；
(2) significant effect of the compounds of this invention reducing blood lipid is better than theaflavin, theaflavin-3-gallate, theaflavin-
The effect of 3 '-gallates and theaflavin -3,3 '-digallic acid ester reducing blood lipid；
(3) the compounds of this invention is significantly better than theaflavin, theaflavin -3- to the therapeutic effect of nonalcoholic fatty liver and does not eat
Sub- acid esters, theaflavin-3'-gallate and theaflavin -3,3 '-digallic acid ester imitate the treatment of nonalcoholic fatty liver
Fruit.
Detailed description of the invention
In order to make the content of the present invention more clearly understood, it below according to specific embodiments of the present invention and combines
Attached drawing, the present invention is described in further detail, in which:
Fig. 1 and Fig. 2 is the liver organization HE dye of 2 groups of rats of model control group and compound in experimental example 3 of the present invention respectively
Color pathological examination result.
Specific embodiment
In following embodiment of the present invention and experimental example, myricetin, rutin, isoquercitrin, Quercetin are commercially available product, purity
>=98% (HPLC detection).
Polyphenol oxidase extracts in accordance with the following methods: extracting the polyphenol oxidase in the object of enzyme source, tool using homogenate method
Body is as follows: weighing 10kg apple, crushes in tissue mashing machine, smashed enzyme source object is taken out, is put into the lemon of 10L pre-cooling
Acid-disodium hydrogen phosphate buffer (pH of buffer 5.5, crospovidone containing 100g PVPP, the EDTA of 20gVc, 1mmol/L),
High-speed tissue mashing machine is homogenized 8min, extracts under 4 DEG C of low temperature 12 hours, leaching liquor obtained by 3 layers of filtered through gauze, by gained filtrate
4 DEG C low-temperature centrifugation 30 minutes, revolving speed 8000r/min, supernatant is apple polyphenol oxidase, and freeze-drying is stand-by.
The source object apple of polyphenol oxidase is replaced with into the kind of pear to get pears polyphenol oxidase；By polyphenol oxidase
Source object apple replaces with fresh tea passes to get tea leaf polyphenols oxidizing ferment.
Embodiment 1The preparation of compound 1
Myricetin and each 150g of rutin are weighed respectively, are dissolved in the citrate-phosphate disodium hydrogen buffer that the pH of 15L is 4.5
In (concentration of substrate 2g/100mL), a certain amount of apple polyphenol oxidase (additive amount 2.5g/L) is added, ventilatory capacity is
15L/min reacts 2 hours at 25 DEG C, and temperature is increased to rapidly 100 DEG C by heating inactivates polyphenol oxidase, is kept for 5 points
Clock.
Polyamide resin column on gained reaction solution is chromatographed, column chromatography diameter height compares for 1:10, applied sample amount and bed volume ratio
It is successively eluted with water, 5% ethanol water, 95% ethanol water for 1:4, loading flow velocity 2BV/h, collects 95% second
Alcohol elutes position, and 40 DEG C of reduced pressure dryings obtain crude extract, is further isolated and purified using suppressing in BUCHI, column chromatography
Specification: crude extract is dissolved in 30% ethanol water (concentration 80mg/ by 15mm*310mm, filler C18, flow velocity 3mL/min
ML it) is used as sample solution, gradient is that 15%-30% ethanol water elutes 3h, 30% ethanol water elutes 2h, 30%-
60% ethanol water elutes 3h, 60%-95% ethanol water and elutes 2h, collects 30% ethyl alcohol aqueous strip solution, 45 DEG C subtract
Pressure is concentrated into no alcohol taste, is freeze-dried, obtains compound 1 (HPLC purity >=98%).
Structure confirmation data is as follows: ESI:m/z 897.2 [M+H]+；1H NMR (600MHz, CD3OD) and13C NMR
(150MHz, CD3OD) as shown in table 1-1:
Table 1-1 compound 11H NMR and13C NMR data
Note: in table 1-1, "-" indicate the position without H, it is same in table 1-2~table 1-3.
Embodiment 2The preparation of compound 2
Myricetin and each 200g of isoquercitrin are weighed respectively, and the citrate-phosphate disodium hydrogen that the pH for being dissolved in 15L is 3.5 is slow
In fliud flushing, a certain amount of tea leaf polyphenols oxidizing ferment (additive amount 2.0g/L) is added, ventilatory capacity 25L/min is anti-at 35 DEG C
It answers 45 minutes, temperature is increased to rapidly 100 DEG C by heating inactivates polyphenol oxidase, is kept for 5 minutes.
Polyamide resin column on gained reaction solution is chromatographed, column chromatography diameter height compares for 1:8, and applied sample amount is with bed volume ratio
1:5, loading flow velocity 2BV/h are successively eluted with water, 5% ethanol water, 95% ethanol water, and 95% ethyl alcohol is collected
Position is eluted, 40 DEG C of reduced pressure dryings obtain crude extract, further isolate and purify using suppressing in BUCHI, column chromatography rule
Lattice: crude extract is dissolved in 35% ethanol water (concentration 80mg/mL) by 15mm*310mm, filler C18, flow velocity 3mL/min
As sample solution, gradient is that 15%-35% ethanol water elutes 3h, 35% ethanol water elutes 2h, 35%-60%
Ethanol water elutes 3h, 60%-95% ethanol water and elutes 2h, collects 35% ethyl alcohol aqueous strip solution, and 45 DEG C of decompressions are dense
It is reduced to no alcohol taste, is freeze-dried, obtains compound 2 (HPLC purity >=98%).
Structure confirmation data is as follows: ESI:m/z 751.1 [M+H]+；1H NMR (600MHz, CD3OD) and13C NMR
(150MHz, CD3OD) as shown in table 1-2:
Table 1-2 compound 21H NMR and13C NMR data
Embodiment 3The preparation of compound 3
Myricetin and each 75g of Quercetin are weighed respectively, are dissolved in the citrate-phosphate disodium hydrogen buffer that the pH of 15L is 4.0
In, a certain amount of pears polyphenol oxidase (additive amount 1.5g/L) is added, it is small to react 1.2 at 30 DEG C by ventilatory capacity 30L/min
When, temperature is increased to rapidly 100 DEG C by heating inactivates polyphenol oxidase, is kept for 5 minutes.
Polyamide resin column on gained reaction solution is chromatographed, column chromatography diameter height compares for 1:10, applied sample amount and bed volume ratio
It is successively eluted with water, 5% ethanol water, 95% ethanol water for 1:4, loading flow velocity 2BV/h, collects 95% second
Alcohol elutes position, and 40 DEG C of reduced pressure dryings obtain crude extract, is further isolated and purified using suppressing in BUCHI, column chromatography
Specification: crude extract is dissolved in 35% ethanol water (concentration 80mg/ by 15mm*310mm, filler C18, flow velocity 3mL/min
ML it) is used as sample solution, gradient is that 15%-35% ethanol water elutes 3h, 35% ethanol water elutes 2h, 35%-
60% ethanol water elutes 3h, 60%-95% ethanol water and elutes 2h, collects 35% ethyl alcohol aqueous strip solution, 45 DEG C subtract
Pressure is concentrated into no alcohol taste, is freeze-dried, obtains compound 3 (HPLC purity >=98%).
Structure confirmation data is as follows: ESI:m/z 589.2 [M+H]+；1H NMR (600MHz, CD3OD) and13C NMR
(150MHz, CD3OD) as shown in table 1-3:
Table 1-3 compound 31H NMR and13C NMR data
Embodiment 4The preparation of theaflavin
Theaflavin can be commercially available product, can be prepared according to method in the prior art, can also be according to this implementation
Prepared by the following method of example: weighing epigallocatechin and each 150g of epicatechin respectively, the pH for being dissolved in 15L is 4
In citrate-phosphate disodium hydrogen buffer, a certain amount of tea leaf polyphenols oxidizing ferment (additive amount 1.5g/L) is added, ventilatory capacity is
20L/min reacts 1.5 hours at 25 DEG C, and temperature is increased to rapidly 100 DEG C by heating inactivates polyphenol oxidase, is kept for 5 points
Clock.
Polyamide resin column on gained reaction solution is chromatographed, column chromatography diameter height compares for 1:10, applied sample amount and bed volume ratio
It is successively eluted with water, 5% ethanol water, 95% ethanol water for 1:4, loading flow velocity 2BV/h, collects 95% second
Alcohol elutes position, and 40 DEG C of reduced pressure dryings obtain crude extract, is further isolated and purified using suppressing in BUCHI, column chromatography
Specification: crude extract is dissolved in 35% ethanol water (concentration 80mg/ by 15mm*310mm, filler C18, flow velocity 3mL/min
ML it) is used as sample solution, gradient is that 15%-35% ethanol water elutes 3h, 35% ethanol water elutes 2h, 35%-
60% ethanol water elutes 3h, 60%-95% ethanol water and elutes 2h, collects 35% ethyl alcohol aqueous strip solution, 45 DEG C subtract
Pressure is concentrated into no alcohol taste, is freeze-dried, obtains compound.It is compared by HPLC-MS and commercially available theaflavin reference substance, it is known that above-mentioned
The above-mentioned compound being prepared is theaflavin.
Embodiment 5The bis- galla turcicas of theaflavin-3-gallate, theaflavin-3'-gallate, theaflavin -3,3 ' -
The preparation of acid esters
Theaflavin-3-gallate, theaflavin-3'-gallate, theaflavin -3,3 '-digallic acid ester can be with
For commercially available product, can be prepared according to method in the prior art, it can also be according to the following method system of the present embodiment
It is standby:
Using Epigallo-catechin gallate (EGCG) and epicatechin as reaction raw materials, carried out according to the condition of embodiment 4
Reaction, can be prepared theaflavin-3-gallate；
Using L-Epicatechin gallate and epigallocatechin as reaction raw materials, carried out according to the condition of embodiment 4
Reaction, can be prepared theaflavin-3'-gallate；
Using Epigallo-catechin gallate (EGCG) and L-Epicatechin gallate as reaction raw materials, according to embodiment 4
Condition reacted, theaflavins-3,3'-bisgallate can be prepared.
Experimental example 1The research of the compounds of this invention antiobesity action
1, experimental material
D12451 (45%) purifying feed high in fat and basal feed are purchased from Research Diets (U.S.).
4 week old male C 57 BL/6 J mouse of SPF grade 108 (is provided by Shanghai Ling Chang Biotechnology Co., Ltd；First initial body
Weight is 11-13g；The sub-cage rearing in plastics cage tool freely ingests and drinks water 7 days, adapts it to environment and quarantine).
2, experimental method
2.1 experimental group
108 mouse are divided into 9 groups, and every group 12,4/cage, respectively blank control group, model control group, compound 1
Group, 2 groups of compound, 3 groups of compound, theaflavin group, theaflavin-3-gallate group, theaflavin-3'-gallate group
With theaflavin -3,3 '-digallic acid ester group.
2.2 medication
Freely ingest drinking-water, blank control group feeding basal feed, model control group and each administration group feeding D12451 high
Rouge purifies feed, and 1 group of compound, 2 groups of compound, 3 groups of compound, theaflavin group, theaflavin-3-gallate group, tea are yellow
Plain -3 '-gallate groups and theaflavin -3,3 '-digallic acid ester group give the compound 1 of the preparation of embodiment 1, reality respectively
It is yellow to apply theaflavin, the tea of the preparation of embodiment 5 prepared by the compound 2 of the preparation of example 2, compound 3 prepared by embodiment 3, embodiment 4
Element -3- gallate, theaflavin-3'-gallate and theaflavins-3,3'-bisgallate, each administration group are administered
1 times/day, dosage is 100mg/kg, and successive administration 8 weeks.
3, experimental data detection and processing
3.1 Testing index
Observe and record the weight and weight gain of each group.
3.2 statistical analysis
Data processing is carried out using 20.0 software of SPSS, group difference uses one-way analysis of variance.
4, experimental result
After being administered 8 weeks, the experimental data of the weight gain of each group mouse is as shown in table 2.
The weight gain of 2 each group mouse weight of table
| Group number | Weight gain weight (g) |
| Blank control group | 10.16±1.50 |
| Model control group | 18.75±1.98## |
| 1 group of compound | 13.08±1.83** |
| 2 groups of compound | 13.21±1.75** |
| 3 groups of compound | 12.96±1.94** |
| Theaflavin group | 15.16±1.88* |
| Theaflavin-3-gallate group | 17.34±1.92 |
| Theaflavin-3'-gallate group | 16.57±1.86 |
| Theaflavin -3,3 '-gallate group | 17.19±1.97 |
P < 0.01 is compared in ## expression with blank control group, and P < 0.01 is compared in * * expression with model control group, and * is indicated and model
Control group compares P < 0.05
As shown in Table 2: (1) after mouse is fed with 8 weeks, compared with blank control group, the weight gain of model control group rat body weight
With extremely significant difference (P < 0.001)；This shows obese model modeling success；
(2) compared with model control group, compound 1,2,3 being capable of extremely significant weight gain (the P < for reducing mouse
0.001)；
(3) compared with model control group, theaflavin has the effect of certain reduction mouse weight gain, and theaflavin -3- is not eaten
Sub- acid esters, theaflavin-3'-gallate and theaflavin -3,3 '-digallic acid ester, which all have, reduces becoming for mouse weight gain
Gesture, but effect is not significant；
(4) compared with model control group, the compounds of this invention 1,2,3 can significantly inhibit the weight gain of mouse, and its
The increased significant effect of mouse weight is inhibited to be better than theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate
Inhibit the increased effect of mouse weight with theaflavin -3,3 '-digallic acid ester.
Experimental example 2The research of the compounds of this invention effect for reducing blood fat
1, experimental material
Cholesterol and sodium taurocholate are purchased from Great Wall pharmaceutcal corporation, Ltd (China, Shanghai).
Feed be it is commercially available, high lipid food include 75% basal feed, 2% cholesterol, 0.5% sodium taurocholate, 15% lard and
7.5% yolk.
4 week old male SD rat of cleaning grade 90 (is provided by Shanghai Ling Chang Biotechnology Co., Ltd；Original body mass is
150-180g；The sub-cage rearing in plastics cage tool freely ingests and drinks water 7 days, adapts it to environment and quarantine).
2, experimental method
2.1 experimental group
90 rat stochastic averaginas are divided into 9 groups, every group 10, respectively 1 group of compound, 2 groups of compound, compound 3
Group, theaflavin group, theaflavin-3-gallate group, theaflavin-3'-gallate group and the bis- no foods of theaflavin -3,3 ' -
Sub- acid esters group, model control group and blank control group.Blank control group is fed with basal feed, other each groups are fed with high lipid food
Diet.
2.2 medication
It freely ingests drinking-water, blank control group is fed with basal feed, and model control group and each administration group are fed with high lipid food,
1 group of compound, 2 groups of compound, 3 groups of compound, theaflavin group, theaflavin-3-gallate group, theaflavin -3 '-galla turcica
Acid esters group and theaflavin -3,3 '-digallic acid ester group give the compound 1 of the preparation of embodiment 1 respectively, prepared by embodiment 2
Theaflavin -3- the galla turcica of theaflavin, the preparation of embodiment 5 prepared by compound 2, the compound 3 of the preparation of embodiment 3, embodiment 4
Acid esters, theaflavin-3'-gallate and theaflavins-3,3'-bisgallate, each administration group are administered once/day, administration
Dosage is 70mg/kg, is administered 7 weeks.
3, experimental data detection and processing
3.1 Testing index
After being administered 7 weeks, rat is taken a blood sample through retroorbital venous clump, is quantitatively examined on automatic biochemistry analyzer using enzymatic method
It is solid to survey its serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein gallbladder
Alcohol (LDL-C).
3.2 statistical analysis
Data processing is carried out using 20.0 software of SPSS, group difference uses one-way analysis of variance.
4, experimental result
After being administered 7 weeks, the experimental result of the biochemical blood parameters of each group rat is as shown in table 3.
The biochemical blood parameters of 3 each group rat of table
P < 0.01 is compared in ## expression with blank control group, and P < 0.01 is compared in * * expression with model control group, and * is indicated and model
Control group compares P < 0.05
As shown in Table 3: (1) compared with model control group, TG, TC, LDL-C reduction of 1,2,3 pair of rat of compound have pole
Significant difference (P < 0.01) shows that TG, TCLDL-C of 1,2,3 pair of hyperlipemia rat of the compounds of this invention all have significant drop
Low effect；
(2) compared with model control group, theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and
There were significant differences (P < 0.05) or has reduction for TG, TC, LDL-C reduction of theaflavin-the 3,3 '-digallic acid ester to rat
Trend；
(3) significant effect of 1,2,3 reducing blood lipid of the compounds of this invention is better than theaflavin, theaflavin-3-gallate, tea
The effect of flavine -3 '-gallate and theaflavin -3,3 '-digallic acid ester reducing blood lipid.
Experimental example 3Research of the compounds of this invention to the preventive and therapeutic action of nonalcoholic fatty liver
1, experimental material
Experimental material of the experimental material of this experimental example with experimental example 2.
2, experimental method
With the experimental group and medication of experimental example 2, difference is only that the experimental group and medication of this experimental example:
Successive administration 4 weeks.
3, experimental data detection and processing
3.1 Testing index
To experiment last day, after etherization, 10% formalin is fixed after taking rat liver to weigh, paraffin section,
Microscopy after HE dyeing: (1) recording the weight and liver weight in wet base of each group, calculates liver index (liver weight/weight * 100%)；(2) right
Model control group and 2 groups of compound of pathology of hepar inspection.
3.2 statistical analysis
Data processing is carried out using 20.0 software of SPSS, group difference uses one-way analysis of variance.
4, experimental result
After being administered 4 weeks, each group rat body weight, liver weight in wet base, liver index are as shown in table 4, pathology of hepar inspection result
As shown in Figs. 1-2.
4 each group rat body weight of table, liver weight in wet base and liver index variation
P < 0.05 is compared in # expression with blank control group, and P < 0.01 is compared in ## expression with blank control group, and * * is indicated and model
Control group compares P < 0.01, and * indicates to compare P < 0.05 with model control group
As shown in Table 4: (1) with model control group compared with, 1,2,3 pair of rat body weight of compound, liver weight in wet base and liver index drop
It is low to have extremely significant difference or significant difference (P < 0.01 or P < 0.05), show 1,2,3 pair of non-alcoholic rouge of the compounds of this invention
Fat hepatomegaly mouse has certain therapeutic effect；
(2) compared with model control group, theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and
Theaflavin -3,3 '-digallic acid ester to rat body weight, liver weight in wet base and liver index reduce there were significant differences (P < 0.05) or
Has the tendency that reduction, but effect is not significant；
(3) therapeutic effect of 1,2,3 pair of nonalcoholic fatty liver of the compounds of this invention is significantly better than theaflavin, theaflavin-
3- gallate, theaflavin-3'-gallate and theaflavin -3,3 '-digallic acid ester are to nonalcoholic fatty liver
Therapeutic effect.
By Fig. 1-2 it is found that model control group rat liver is loose, color is partially light, and liver cell diffuses sex vesicle steatosis；
2 groups of liver fats of compound are steeped obvious number and are reduced, and scale mitigates.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (10)
1. the compound with structure shown in formula (I),
Wherein, R1、R2Be independently from each other H, by In
At least one is formed by glycosyl residue.
2. compound according to claim 1, which is characterized in that
R1Selected from H, byAt least one of be formed by glycosyl residue, R2Selected from H.
3. compound according to claim 1 or 2, which is characterized in that
R1Selected from H,
4. compound according to claim 1-3, which is characterized in that formula (I) compound represented is selected from:
5. the pharmaceutically acceptable salt of the described in any item compounds of claim 1-4, ester, prodrug, solvate or its crystalline substance
Type.
6. a kind of pharmaceutical preparation, which is characterized in that with the described in any item compounds of claim 1-4, its is pharmaceutically acceptable
Salt, ester, prodrug, solvate or its crystal form be active constituent, according to common process, customary adjuvant be added be made and clinically may be used
Tablet, capsule, powder, mixture, pill, granule, syrup, emplastrum, suppository, aerosol, ointment or the note of receiving
Penetrate agent.
7. a kind of method for preparing the described in any item compounds of claim 1-4, which is characterized in that chemical combination shown in formula (II)
Object and formula (III) compound represented pass through enzymatic reaction under the action of polyphenol oxidase up to formula (I) compound represented；
8. preparation method according to claim 7, which is characterized in that shown in formula (II) compound represented and formula (III)
The molar ratio of compound is (1:2)~(2:1)；
Using citrate-phosphate disodium hydrogen buffer as reaction solution, formula (II) compound represented and formula (III) compound represented
Total concentration in reaction solution is 1~2.7g/100mL.
9. preparation method according to claim 7 or 8, which is characterized in that pH value in reaction is 3.5~4.5, and reaction temperature is
25~35 DEG C, the reaction time is 0.75~2h, and the additional amount of the polyphenol oxidase is 1.5~2.5g/L, minute ventilation volume
For 1~2 times of amount of the reaction solution volume.
10. the described in any item compounds of claim 1-5 or pharmaceutical preparation as claimed in claim 9 in preparation there is weight-reducing to make
Application in drug or health care product；
Preferably, the application is the application in the drug or health care product that preparation has effect for reducing blood fat；
It is further preferred that the application is the application in the drug or health care product of preparation prevention or treatment fatty liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710724964.4A CN109422786A (en) | 2017-08-22 | 2017-08-22 | Benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710724964.4A CN109422786A (en) | 2017-08-22 | 2017-08-22 | Benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109422786A true CN109422786A (en) | 2019-03-05 |
Family
ID=65498645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710724964.4A Withdrawn CN109422786A (en) | 2017-08-22 | 2017-08-22 | Benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109422786A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109422785A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones and preparation method thereof and purposes |
| CN109422787A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones are like object and preparation method thereof and purposes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102427807A (en) * | 2009-05-21 | 2012-04-25 | 三得利控股株式会社 | Anti-obesity agent comprising compound containing benzotropolone ring |
| CN109422714A (en) * | 2017-08-22 | 2019-03-05 | 苏州禾研生物技术有限公司 | Benzo Tropolones compound and preparation method thereof and purposes |
| CN109422785A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones and preparation method thereof and purposes |
| CN109422787A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones are like object and preparation method thereof and purposes |
-
2017
- 2017-08-22 CN CN201710724964.4A patent/CN109422786A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102427807A (en) * | 2009-05-21 | 2012-04-25 | 三得利控股株式会社 | Anti-obesity agent comprising compound containing benzotropolone ring |
| CN109422714A (en) * | 2017-08-22 | 2019-03-05 | 苏州禾研生物技术有限公司 | Benzo Tropolones compound and preparation method thereof and purposes |
| CN109422785A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones and preparation method thereof and purposes |
| CN109422787A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones are like object and preparation method thereof and purposes |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109422785A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones and preparation method thereof and purposes |
| CN109422787A (en) * | 2017-08-22 | 2019-03-05 | 苏州凯祥生物科技有限公司 | Benzo Tropolones are like object and preparation method thereof and purposes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8940789B2 (en) | Neurite elongation agent, memory-improving agent and anti-Alzheimer agent comprising 4′-demethylnobiletin or 4′-demethyltangeretin as active ingredient, and process for production of the compound | |
| CN1972701A (en) | Appetite-suppressing compositions and methods | |
| US20160067209A1 (en) | Pterocarpan compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of metabolic disease or complication thereof, or for antioxidant containing the same as an active ingredient | |
| CN109422714A (en) | Benzo Tropolones compound and preparation method thereof and purposes | |
| US20080160119A1 (en) | Sesquiterpenoid Derivatives Having Adipocyte Differentiation Inhibitory Effect | |
| WO2013108822A1 (en) | Des(rhamnosyl) acteoside-containing olive extract | |
| CN109422786A (en) | Benzo Zhuo phenol ketone derivatives and preparation method thereof and purposes | |
| CN109422785A (en) | Benzo Tropolones and preparation method thereof and purposes | |
| CN109422787A (en) | Benzo Tropolones are like object and preparation method thereof and purposes | |
| KR20220000892A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of barley sprout | |
| KR20030044846A (en) | Acetylcholinesterase inhibitor comprising (-)epigallocatechin gallate and pharmaceutical preparation, food product and feed product containing the same | |
| EP2120924B1 (en) | An anti-diabetic extract of honeybush | |
| JP2010059104A (en) | Xanthine oxidase inhibitor | |
| KR101676297B1 (en) | Composition for supressing of blood sugar level | |
| KR100979459B1 (en) | Tetracera scandens extracts and 4H-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated L6 muscle cells | |
| EP3117825A1 (en) | Oral formulation comprising berberine and morus alba extract | |
| CN111297847B (en) | Application of amomum kravanh extract in preparation of alpha-glucosidase inhibitor medicine | |
| KR100550358B1 (en) | Food product and feed product comprising extract of Yak-kong (Rhynchosia nolubilis or Rhynchosia volubilis) for Alzheimer's disease, dementia, amyosthenia of smooth muscle, and glaucoma | |
| US10961176B2 (en) | Compound hexadecaphlorethol isolated from Ishige okamurae and use thereof | |
| KR20190142672A (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
| KR101145237B1 (en) | Alkaloid compounds as activators of DDAH promoter from Evodia rutaecarpa and compositions for prevention and treatment effects of islet cellular apoptosis and diabetic nephropathy containing the same as an active ingredient | |
| KR102069125B1 (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
| KR101719015B1 (en) | Pharmaceutical composition for preventing or treating obesity or metabolic disease comprising prunetin as an active ingredient | |
| TW201130487A (en) | Xanthine oxidase inhibitor | |
| JP2009269896A (en) | Raw material of anti-diabetic food or medicine, and anti-diabetic food or medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190305 |
|
| WW01 | Invention patent application withdrawn after publication |